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Background: Amyotrophic lateral sclerosis (ALS) is a fatal disorder involving the degeneration and loss of motor
neurons. The mechanisms of motor neuron loss in ALS are unknown and there are no effective treatments. Defects
in the distal axon and at the neuromuscular junction are early events in the disease course, and zebrafish provide a
promising in vivo system to examine cellular mechanisms and treatments for these events in ALS pathogenesis.
Results: We demonstrate that transient genetic manipulation of zebrafish to express G93A-SOD1, a mutation
associated with familial ALS, results in early defects in motor neuron outgrowth and axonal branching. This is
consistent with previous reports on motor neuron axonal defects associated with familial ALS genes following
knockdown or mutant protein overexpression. We also demonstrate that upregulation of growth factor signaling is
capable of rescuing these early defects, validating the potential of the model for therapeutic discovery. We
generated stable transgenic zebrafish lines expressing G93A-SOD1 to further characterize the consequences of
G93A-SOD1 expression on neuromuscular pathology and disease progression. Behavioral monitoring reveals
evidence of motor dysfunction and decreased activity in transgenic ALS zebrafish. Examination of neuromuscular
and neuronal pathology throughout the disease course reveals a loss of neuromuscular junctions and alterations in
motor neuron innervations patterns with disease progression. Finally, motor neuron cell loss is evident later in the
disease.
Conclusions: This sequence of events reflects the stepwise mechanisms of degeneration in ALS, and provides a
novel model for mechanistic discovery and therapeutic development for neuromuscular degeneration in ALS.
Keywords: Amyotrophic lateral sclerosis (ALS), Motor neuron (MN), Zebrafish, Cu2+/Zn2+ superoxide dismutase
(SOD1), G93A-SOD1, Neuromuscular junction, NeurodegenerationBackground
Amyotrophic lateral sclerosis (ALS) is an adult-onset, re-
lentlessly progressive, and ultimately lethal neuromuscu-
lar disease involving the degeneration and loss of motor
neurons (MNs). Effective treatments for ALS have been
elusive due to the fact that the mechanisms of MN loss
in ALS are unknown. It is likely that multiple cell types
within the MN microenvironment and multiple mechan-
isms contribute to ALS pathogenesis [1,2]. While MN
death is associated with caspase-mediated programmed
cell death, neuromuscular junction (NMJ) defects and
axonal degeneration are evident early in the disease* Correspondence: efeldman@umich.edu
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reproduction in any medium, provided the orcourse before symptom onset and MN loss [3,4]. Under-
standing the causes of NMJ and axonal degeneration in
ALS and identifying therapies that protect against these
early insults represent the best strategy for preventing
the irreversible loss of MNs.
The majority of ALS is sporadic with unknown eti-
ology (90-95%); however, the remaining cases are familial
(fALS) and have been linked to genetic mutations in
genes such as Cu2+/Zn2+ superoxide dismutase (SOD1),
Alsin (Als2), dynactin, angiogenin, senataxin, vesicle-
associated membrane protein/synaptobrevin-associated
membrane protein B, TAR DNA binding protein 43
(TDP43), fused in sarcoma (FUS), optineurin, and ubi-
quilin 2, or a hexanucleotide repeat expansion in
C9ORF72 [5-18]. SOD1 mutations are associated with
10-20% of fALS cases and currently more than 150al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are associated with a toxic gain of unknown function.
Many in vitro and in vivo models expressing mutant
SOD1 have been developed to study disease pathogen-
esis [2,19]. G93A-SOD1 is the most thoroughly charac-
terized ALS mutation and expression in primary MN
cultures results in caspase activation and MN death
[20,21]. In vivo ALS models, including transgenic G93A-
SOD1 mice, exhibit MN degeneration, muscle weakness
and early lethality, resembling the human ALS disease
course [22,23]. G93A-SOD1 mice also show denervation
at NMJs, defects in axonal transport, and axonal degen-
eration well before the onset of clinical symptoms, which
supports a “dying-back” mechanism of MN degeneration
[24,25]. Thus, understanding and targeting the distal de-
generation that occurs prior to the irreversible loss of
MNs is imperative for developing effective therapies for
ALS.
Recently, zebrafish have been gaining momentum as an
emerging technology for the study of neurodegenerative
diseases [26,27]. Zebrafish are ideal for the development
of novel strategies to understand ALS pathogenesis and
screen potential therapies due to the fact that they de-
velop quickly, have large numbers of offspring, are less
expensive than rodent models, and they are easily amen-
able to genetic manipulation. Zebrafish neuromuscular
physiology is also similar to humans, neuromuscular de-
velopment is well characterized and rapid, and many
tools exist to closely examine MN and muscle pathology
in zebrafish. Furthermore, mechanistic insight into ALS
pathogenesis could also be possible through combination
with various tissue- and organelle-specific transgenic
reporter zebrafish lines available [28-31], and some
neurodegenerative disease models have already been
developed. Spinal muscular atrophy, a neurodegenera-
tive disease involving MNs, has been successfully mod-
eled in zebrafish [32-34], and transient expression of
select ALS mutations has also been reported. Transient
overexpression of mutant SOD1 or mutant FUS induces
an axonopathy phenotype at 30 hours post-fertilization
(hpf ) characterized by decreased axon length and aber-
rant branching [35,36], as does knockdown of fus, als2,
and elp3 [35,37,38]. Similarly, knockdown of tdp43 or
expression of mutant TDP43 in zebrafish embryos results
in an axonal phenotype early in development, which is
further evidenced in swimming deficits at 48 hpf [39].
While these results reflect an effect of mutant ALS pro-
teins on developing MN axons, the transient expression
in these models limits the amount of insight that can be
gained regarding the mechanisms of progressive neuro-
degeneration that is characteristic of ALS.
To investigate ALS disease pathogenesis and progres-
sion in zebrafish, we generated novel stable transgenic
zebrafish ubiquitously expressing G93A-SOD1. At theonset of this project, no transgenic ALS zebrafish mod-
els were established to our knowledge; however, in 2010
the Beattie laboratory reported the generation and
characterization of transgenic zebrafish lines ubiqui-
tously expressing zebrafish G93R-sod1 [40]. This model
exhibits motor deficits, MN degeneration and loss, and
effects on survival [40] that are characteristic of ALS,
validating our approach to generate and utilize the trans-
genic ALS zebrafish model described in this report. Our
initial experiments verified the potential of human
G93A-SOD1 to induce the previously reported motor
axon defects, and we also demonstrated attenuation of
these MN axonal defects with a known neuroprotective
factor, insulin-like growth factor-I (IGF-I). We then
established stable transgenic zebrafish lines expressing
GFP-tagged human G93A-SOD1 using Tol2-mediated
transgenesis. Characterization of our stable transgenic
G93A-SOD1-GFP zebrafish revealed motor deficits that
coincide with defects at the NMJ and subsequent altera-
tions in neuromuscular innervation. We also observe
MN loss later in the disease course, which supports a se-
quence of events that resemble human ALS pathogen-
esis. Overall, this report describes our detailed
examination of MN axonal pathology, NMJ integrity,
and MN loss in the context of disease onset and pro-
gression in a novel in vivo zebrafish ALS model that will
be instrumental in future studies of ALS disease
mechanisms and therapeutic development.Results
Transient overexpression of G93A-SOD1 in zebrafish
causes motor axon defects
Before generating stable transgenic G93A-SOD1 zebra-
fish, we first examined developing zebrafish MN axons
following transient human G93A-SOD1 expression.
Microinjection of G93A-SOD1 RNA (0 – 100 ng/μl),
which was generated from a pCS2 vector that enables ef-
ficient expression in zebrafish, results in transient over-
expression of the protein as confirmed by western
blotting (data not shown). SV2 immunohistochemistry
(IHC) reveals that G93A-SOD1 expression results in ab-
normal premature branching of motor axons at 30 hpf
compared to controls (Figure 1A, *). We also detect a
dose-dependent effect of G93A-SOD1 expression on
axon length compared to uninjected control (UIC)
embryos, with significant decreases observed at concen-
trations as low as 10 ng/μl (Figure 1B). Specifically, axon
length is decreased by 13.2%, 17.9%, and 19.1% at doses
of 10, 50, and 100 ng/μl G93A-SOD1 RNA, respectively.
Co-injection of G93A-SOD1 RNA (50 ng/μl) with igf-I
RNA (200 ng/μl) demonstrates that these defects are
attenuated by IGF-I upregulation (Figure 1C), a known
neuroprotective strategy in ALS model systems [41].
Figure 1 Effects of G93A-SOD1 on developing zebrafish MN axons. Zebrafish embryos at the 1-4 cell stage were microinjected with wtSOD1,
G93A-SOD1 and/or igf-I RNA after timed mating of adult AB strain zebrafish and underwent IHC with the SV2 antibody at 30 hpf to visualize MN
axons. (A) SV2 IHC demonstrates increased branching of motor axons, represented by (*) in embryos injected with G93A-SOD1 (50 ng/μl) RNA,
compared to embryos injected with wtSOD1 (50 ng/μl) RNA. 20x magnification confocal images; scale bar equals 50 μm. (B) Measurement of
axon length in embryos injected with 0-100 ng/μl G93A-SOD1 RNA reveals a dose-dependent decrease in MN axon length; * P < 0.001 compared
to UIC. (C) Co-injection of igf-I RNA (I; 200 ng/μl) attenuates the effects of G93A-SOD1 (G; 50 ng/μl) on axon length. No significant effects of
wtSOD1 (W; 50 ng/μl) are observed, regardless of IGF-I expression. * P < 0.001 compared to UIC.
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axon length (Figure 1C). IGF-I upregulation was con-
firmed by assessing downstream activation of Akt and
p44/42 mitogen activated protein kinase (MAPK) signal-
ing and SOD1 expression was confirmed for all clutches
using western blotting (data not shown). Together, these
findings demonstrate that expression of mutant human
SOD1 in zebrafish results in a motor axon phenotype
that is amenable to therapeutic intervention, validating
the potential usefulness of zebrafish as a model for in-
vestigating ALS pathogenesis and drug discovery.
Generation of stable transgenic G93A-SOD1 zebrafish
lines
Stable transgenic ALS zebrafish lines were successfully
generated for these studies using Tol2-mediated trans-
genesis. Coinjection of pDEST-CMV-G93A-SOD1-GFP
cDNA (Figure 2A), in combination with Tol2 transpo-
sase RNA, resulted in random insertion of the Tol2-
flanked transgene into the zebrafish genome. Preliminary
studies comparing G93A-SOD1 and G93A-SOD1-GFP
RNA injections did not demonstrate an effect of utilizing
a GFP-fusion construct on the MN axonal phenotype
(data not shown). Germline transmission was confirmed
by PCR analysis of genomic DNA from F1 generation
embryos for the human transgene (Figure 2B). Western
blotting of protein lysates from F1 generation embryos
for SOD1 expression (Figure 2C) demonstrated that
G93A-SOD1-GFP expression levels were approximately
64% that of the endogenous zebrafish wtSOD1. Trans-
genic lines expressed the GFP-fusion protein ubiqui-
tously throughout the lifespan of the zebrafish
(Figure 2D-E). F2 generation zebrafish from 2 independ-
ent lines were characterized for these studies, the G93A-
SOD1-GFP.umich1 (G1) and the G93A-SOD1-GFP.
umich21 (G21) lines, to minimize the chance of anypositional effects of the insertions. All presented data is
for the G21 line, as both lines exhibited similar morpho-
logical phenotypes.Symptom onset in transgenic G93A-SOD1 zebrafish
Disease onset in non-transgenic AB control or trans-
genic G93A-SOD1-GFP zebrafish was determined by
quantitative assessment of spontaneous swimming be-
havior using the Noldus Activity Monitoring System as a
clinical correlate to extremity weakness observed in ALS
patients (Figure 3). The system integrates movements
over a defined interval for various activity parameters,
including swimming velocity and time spent swimming
versus resting. Examination of spontaneous swim speeds
demonstrate that, while the swimming velocity at
10 weeks of age is similar for control and transgenic zeb-
rafish lines, the transgenic G93A-SOD1-GFP zebrafish
exhibit an overall slower velocity throughout the disease
course compared to AB control zebrafish (Figure 3C).
Transgenic G93A-SOD1-GFP zebrafish also tend to
spend more time resting as the disease progresses
(Figure 3D). Linear regression analysis, on the other
hand, reveals that the overall change in swimming vel-
ocity between 10-60 weeks of age is approximately zero
for both lines; slopes equal 0.0076 and -0.0889 for con-
trol AB and transgenic G21 zebrafish, respectively
(Figure 3C). This could reflect variable onset among the
transgenic G93A-SOD1-GFP zebrafish line that does not
reach significance, or may indicate that significant differ-
ences in progression might occur later than the 60 week
time point. Analysis of the overall change in time resting,
however, is significantly different between 10-60 weeks
of age for the two lines (Figure 3D). Taken together,
these swimming behaviors represent motor dysfunction
and decreased endurance that are consistent with a
Figure 2 Transgenic ALS zebrafish. Transgenic ALS zebrafish are generated by Tol2-mediated transgenesis. (A) Constructs include a 5’ CMV
promoter, human G93A-SOD1 and a 3’ EGFP C-terminal fusion protein including a SV40 late poly A tail. Microinjection of construct cDNA in the
presence of Tol2 transposase RNA facilitates efficient, random integration of the transgene via flanking Tol2 sites. (B) PCR of genomic DNA
extracted from 24 hpf F1 generation embryos demonstrates germline transmission of the G93A-SOD1-GFP transgene, confirming successful
generation of the transgenic lines. (C) Western immunoblotting of protein lysates from 24 hpf F1 generation embryos demonstrates expression
levels of the G93A-SOD1-GFP protein in three independent clutches of transgenic embryos. (D-E) Images of an F1 embryo (D; 24 hpf) and adult
(E; 3 months of age) from the G21 G93A-SOD1-GFP transgenic line demonstrate stable ubiquitous expression of the fusion protein throughout
the zebrafish lifespan.
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and progression of disease in transgenic ALS zebrafish.
NMJ and axon pathology in transgenic G93A-SOD1
zebrafish
Effects at the distal axon and NMJ are one of the earliest
defects in ALS [3,4,24,25]; therefore, we next investigated
neuromuscular pathology in AB control and transgenic
G93A-SOD1-GFP zebrafish. NMJ integrity was first exam-
ined by quantifying the percentage of colocalized postsy-
naptic α-bungarotoxin (αBTX)-positive acetylcholine
receptor (AChR) clusters and SV2/neurofilament (NF)-
positive MN axons (Figure 4A-D; arrowheads depict
defects at NMJs). At 10 weeks of age, no differences
were observed between control and transgenic G93A-
SOD1-GFP zebrafish; however, transgenic G93A-SOD1-
GFP zebrafish exhibited a significant loss of intact NMJs
after 20 weeks of age that persisted through the 60 week
time point (Figure 4E). We next examined how MNs
innervated the muscle fibers by qualitatively scoring the
innervation patterns at each time point as long, moder-
ately branched, or complex (Figure 5). Control AB zeb-
rafish predominantly exhibited long or moderately
branched axons at all examined time points (Figure 4A
and Figure 5B), whereas the percentage of complexbranched fibers increased around 30 weeks of age in the
transgenic G93A-SOD1-GFP zebrafish (Figure 4B and
Figure 5B). Together, these data reveal disruption at the
NMJ with disease progression in transgenic G93A-
SOD1-GFP zebrafish that is followed by alterations in
MN innervation patterns that may reflect compensatory
remodeling of NMJs.
MN loss in transgenic G93A-SOD1 zebrafish
Axonal and NMJ degeneration is followed by MN loss in
ALS patients and transgenic ALS rodents [3,42],
prompting us to next examine MN numbers in the
spinal cord of transgenic G93A-SOD1-GFP zebrafish.
Spinal cord cross-sections from control AB and trans-
genic G93A-SOD1-GFP zebrafish were labeled with Cre-
syl violet Nissl stain and MN loss was evaluated by
quantifying the number of large MN cell bodies per ven-
tral horn (Figure 6B-C, arrowheads), an approach vali-
dated using transgenic HB9:mGFP zebrafish [28] which
express GFP under control of the MN-specific HB9 pro-
moter (Figure 6A). Control AB zebrafish exhibited a
similar number of MNs per ventral horn at every time
point examined, whereas transgenic G93A-SOD1-GFP
zebrafish exhibited an approximate 50% loss in MN
number by 30 weeks of age (Figure 6D). Overall, our
Figure 3 Activity monitoring in transgenic ALS zebrafish. (A): Representative experimental layout for monitoring spontaneous swimming
behavior of 20 week old control (wells 1-3) and transgenic G93A-SOD1-GFP (wells 4-6) zebrafish using the Noldus Larvae Activity Monitoring
System. (B) Movement tracks extrapolated from a 1 minute trial by EthoVision for analysis of multiple different activity parameters. (C) While
minimal differences are observed in the spontaneous activity levels of transgenic and control zebrafish throughout the disease course, transgenic
G93A-SOD1-GFP zebrafish exhibit a consistently lower swimming velocity relative to age-matched AB controls. (D) As the disease progresses,
transgenic G93A-SOD1-GFP zebrafish spend more time resting than age-matched control AB zebrafish. * P < 0.01 compared to AB control slope.
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results in alterations in swimming behavior, NMJ de-
nervation and subsequent effects on NMJ innervation
patterns which coincide with MN degeneration and loss.
Discussion
ALS is a relentlessly progressive neuromuscular disease
with no effective treatments. While the cause of MN de-
generation in ALS is unknown, multiple lines of evi-
dence support a “dying-back” phenomenon that is
characterized by defects at the NMJ and in distal MN
axons which is then followed by subsequent MN loss
[3,4,24,42]. In vitro studies demonstrate protective
effects of caspase inhibition and growth factor therapies
on MN survival [21,41]. However, studies in in vivo mod-
els indicate that treatments targeted at MN loss have lim-
ited, if any, impact on disease symptoms or survival
[20,43,44] and that neuroprotective strategies targeted at
muscle and NMJs such as growth factor therapies improve
symptom onset and severity [24,41,45,46]. Clinical transla-
tion of such strategies, however, has not yet been rea-
lized and improved treatments for ALS are required.
Because defects in distal axons and at NMJs occur be-
fore symptom onset and MN loss in ALS, comprehend-
ing the mechanisms of ALS neuromuscular pathogenesis
is essential for the development of therapies targeted atevents prior to the irreversible loss of MNs. Detailed
characterization of neuromuscular morphological altera-
tions is possible in zebrafish; therefore, we investigated
the effects of G93A-SOD1 expression on zebrafish MNs
and NMJs.
In recent years, a handful of studies have demon-
strated the consequences of transient expression or
knockdown of select ALS mutant proteins in zebrafish
embryos [35-39]. Expression of mutant forms of SOD1,
for example, induce early defects in MNs including
decreased axon length and aberrant branching at 30 hpf,
which are attenuated or exacerbated by vascular endo-
thelial growth factor upregulation or knockdown, re-
spectively [36]. Therefore, we first examined the effects
of transient human G93A-SOD1 on zebrafish embryo
MNs. Because RNA was generated from a pCS2-based
construct known to elicit efficient high-level expression
in zebrafish, we utilized a dose range that was between
10- to 100-fold lower than the previous report. As seen
in Figure 1, our findings confirm the previous axonopa-
thy findings, and further demonstrate that significant
effects can be observed even with low levels of G93A-
SOD1 RNA. We then examined the therapeutic efficacy
of IGF-I upregulation by co-injecting igf-I RNA with
G93A-SOD1 RNA and assessing axonal development.
Despite the fact that clinical translation of IGF-I
Figure 4 Neuromuscular junction integrity in transgenic ALS zebrafish. NMJs in transverse muscle sections from control AB and transgenic
G93A-SOD1-GFP zebrafish were examined at multiple timepoints after αBTX staining (red) to label AChR clusters in the muscle fibers and SV2/NF
IHC (green) to label MNs. Colocalization (yellow) is apparent at intact NMJs. (A-B) Representative control AB zebrafish (A) exhibit long axons with
multiple synapses, whereas transgenic G93A-SOD1-GFP zebrafish (B) exhibit shorter axons and varied innervation patterns with some denervated
NMJs (arrowheads). 60x oil magnification confocal images; scale bar = 20 μm. (C-D) A representative image of an individual neuron, with images
included as both separated and merged fluorescent channels (C) and visualized with orthogonal XZ and YZ views of the z-series confocal image
(D), validates that colocalization of SV2/NF and αBTX is representative of NMJs. 60x oil magnification confocal images; scale bar = 20 μm. (E)
Quantification of SV2/NF:αBTX colocalization in 10-60 week old control AB and transgenic G93A-SOD1-GFP zebrafish. * P < 0.0001 compared to
age-matched AB controls.
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expected outcomes, IGF-I has been extensively studied
for ALS. In vitro and in vivo studies demonstrate that
IGF-I activates neuroprotective signaling pathways and
provides protection to MNs and at NMJs [41]. Along
those lines, IGF-I is capable of preventing the decreased
axon length observed with G93A-SOD1 expression inzebrafish embryos (Figure 1C). Together with the pre-
vious report [36], these data demonstrate an effect of
low levels of human G93A-SOD1 on zebrafish MNs
that is amenable to neuroprotective intervention, pro-
viding rationale for the generation of stable transgenic
G93A-SOD1 zebrafish lines to examine neuromuscular
pathogenesis in ALS.
Figure 5 Neuromuscular innervation characterization in transgenic ALS zebrafish. Analysis of innervation patterns in 10-60 week old
control AB and transgenic G93A-SOD1-GFP zebrafish. (A) Axons are scored as long (score = 1), moderately branched (scores = 2 or 3) or complex
(score = 4+), as demonstrated in representative images. (B) Quantification of scoring results in 10-60 week old control AB and transgenic
G93A-SOD1-GFP zebrafish. * P < 0.01 compared to age-matched AB controls.
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and multiple approaches exist for the generation of
stable transgenic disease models. The transgenic zebra-
fish lines described in this study (Figure 2) wereFigure 6 MN loss in transgenic ALS zebrafish. Spinal cord cross section
(purple) to label MNs. (A) Representative low power images from control A
Inset zoomed images of the spinal cord ventral horn from AB (A”) and tran
number based on cell body size and localization to the ventral horn; scale
transgenic G93A-SOD1-GFP (C) zebrafish at 60 weeks of age. Arrowheads d
(D) Quantification of MN counts per ventral horn in 30, 40 and 60 week old
compared to age-matched AB controls.developed using Tol2-mediated transgenesis. Briefly,
constructs were generated by multisite Gateway cloning
which provides a simple approach to generate Tol2-
flanked constructs with various promoters and fusions from 30-60 week old zebrafish were stained with Cresyl violet Nissl
B zebrafish is provided for orientation purposes; scale bar = 200 μm.
sgenic HB9:mGFP (A’) zebrafish validate our approach to quantify MN
bar = 25 μm. (B-C) Representative images from control AB (B) and
enote motor neurons; 20X magnification images; scale bar = 100 μm.
control AB and transgenic G93A-SOD1-GFP zebrafish. * P < 0.0001
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tion in the presence of transposase [47]. The CMV pro-
moter we used is derived from the pCS2+ vector used in
our transient studies, and a C-terminal GFP-fusion
allows for easy detection of germline transmission and
confirmation of cellular expression patterns. Confirm-
ation that utilization of a GFP-fusion construct does
note exacerbate the phenotype was supported by prelim-
inary studies comparing transient expression of G93A-
SOD1 and G93A-SOD1-GFP in embryos (data not
shown). Other reports also demonstrate that GFP ex-
pression does not affect the mutant SOD1 phenotype in
embryos [36], and the use of GFP in transgenic tissue-
specific reporter zebrafish lines like HB9:mGFP zebrafish
that express GFP in MNs [28] provide further evidence
supporting our approach. The Tol2-based transposon
system supports dramatically increased transgenesis effi-
ciencies [48], and using this approach, we were able to
establish 6 independent transgenic G93A-SOD1-GFP
zebrafish lines. The G1 and G21 lines characterized for
these studies exhibit ubiquitous expression of the trans-
gene that persists throughout the zebrafish lifespan and
through multiple generations.
Transgenic zebrafish are an emerging model for the
study of neurodegenerative diseases and at the initiation
of this project, long-term data was not available on how
chronic G93A-SOD1 expression, or late-onset neurode-
generation in general, would affect zebrafish. Therefore,
we first examined swimming behavior as a correlate to
muscle weakness observed in ALS patients using the
Noldus Larvae Activity Monitoring System. Spontaneous
swimming behavior was regularly monitored for quanti-
fication of swim speed and duration of movement during
a defined interval. Linear regression analysis of AB con-
trol and transgenic G93A-SOD1-GFP zebrafish swim-
ming velocity between 10 and 60 weeks of age
(Figure 3C) did not reveal a significant difference in
overall swim speed change, or slope, between the 2 lines.
What is important to note, however, is that examination
of the individual time points reveals similar swim speeds
at 10 weeks of age, whereas apparent differences in the
degree of movement emerge after 20 weeks of age be-
tween the 2 lines, with the transgenic G93A-SOD1-GFP
zebrafish consistently exhibiting a trend of slightly
slower swim speeds. Transgenic G93A-SOD1-GFP zeb-
rafish, however, do tend to spend more time resting at
advanced time points compared to controls (Figure 3D).
These findings may indicate that, although there are no
striking changes in locomotor potential between 10-
60 weeks of age in either line, the increased time resting
could reflect a higher tendency for fatigue in the trans-
genic G93A-SOD1-GFP zebrafish that may precede and
potentially predict later motor phenotypes. Given the
drastic motor deficits that appear in rodent ALS models[22,49], these modest effects were initially surprising,
but during the course of these studies the Beattie labora-
tory reported the first generation and characterization of
a transgenic ALS zebrafish model [40]. In that study, the
transgenic zebrafish overexpress zebrafish G93R-sod1
and exhibit decreased swimming endurance at 12 and 16
mo of age compared to non-transgenic controls, as mea-
sured by calculating critical swimming speeds against an
increasing current flow [40]. These findings suggest that
more drastic effects on movement behavior in our model
may not be apparent within the 60 week time frame
examined and support the continued evaluation of
swimming behavior in our transgenic lines, and also sug-
gest the possibility that muscle strength defects in our
model may become apparent by exploring additional
assays for motor function.
As previously described, neuromuscular defects are
apparent in ALS rodent models and patients well before
symptom onset and MN loss [3,4]; therefore, we next
performed a detailed pathological characterization of
NMJs and MNs in control and transgenic G93A-SOD1-
GFP zebrafish. Techniques to quantify NMJ innervation
by MNs are well-established in rodents [25,45,50,51] and
larval zebrafish [52-55], however, only limited informa-
tion regarding visualization and quantification of juven-
ile and adult zebrafish NMJ integrity are available
[32,56]. For the current studies, we labeled presynaptic
MNs and postsynaptic AChR clusters with SV2/NF and
αBTX, respectively, and quantified the number of intact
NMJs in control AB and transgenic G93A-SOD1-GFP
zebrafish between 10 and 60 weeks of age (Figure 4).
Transgenic G93A-SOD1-GFP zebrafish exhibited a sig-
nificant loss of intact NMJs at 20 weeks of age that was
consistent across the remaining time points. These
effects at the NMJ even in the absence of significant
symptomatic affects are consistent with those observed
in rodent ALS models. Transgenic G93A-SOD1 mice ex-
hibit a 40% reduction in the number of innervated NMJs
at 47 days of age, while symptomatic onset does not
occur until around 80 days of age [3]. The importance of
NMJ maintenance is further supported by a study where
muscle-specific expression of mutant SOD1 in mice pro-
moted NMJ defects and distal axonal degeneration [57].
Interestingly, we noticed that this early decrease in NMJ
integrity at 20 weeks of age was subsequently followed
by alterations in the innervation patterns of the muscle
that became apparent at the 30 week time point. While
imaging at earlier time points revealed long axons that
synapse along longitudinal sections of myofibers, later
time points exhibited more branched nerve fibers that
synapsed across multiple myofibers (Figure 5). These
changes are significant in transgenic G93A-SOD1-GFP
zebrafish beginning at 30 weeks of age, and may reflect
compensatory reinnervation of myofibers as previously
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lows NMJ denervation and distal axonal degeneration in
patients and rodent ALS models [3,42]; therefore, we
also quantified MN numbers in transgenic G93A-SOD1-
GFP zebrafish between 30-60 weeks of age. We observed
an approximate 50% reduction in the number of large
MN cell bodies in the ventral horn of transgenic G93A-
SOD1-GFP zebrafish spinal cords at 40 weeks of age
compared to age-matched controls (Figure 6). This coin-
cides with the sequence of events in ALS rodent models,
as MN loss is evident around 100 days in G93A-SOD1
mice, relative to initial NMJ defects as early as 47 days,
and death at 131 days [3]. A timeline summarizing the
sequence of observed morphological alterations in our
transgenic G93A-SOD1-GFP zebrafish is depicted in
Figure 7.
This characterization of our novel transgenic G93A-
SOD1-GFP zebrafish supports and builds upon the pre-
vious findings in transgenic G93R-sod1 zebrafish [40].
The transgenic G93R-sod1 zebrafish exhibit a small but
significant reduction in NMJ innervation at 11 days
post-fertilization (dpf) in transgenic larvae, and a more
significant loss of NMJ innervation at 12 months of age
[40]. While intermediate time points were not described,
these findings coincide with our later observations of
NMJ loss between 40-60 weeks of age, and reflect the
fact that significant NMJ defects are evident as early as
20 weeks of age in our model. MN loss is also evident in
both models, with our transgenic G93A-SOD1 zebrafish
exhibiting an approximate 50% reduction in MN num-
bers by 40 weeks of age, and the transgenic G93R-sod1
zebrafish having a 38% reduction in MN numbers at
end-stage disease. In addition, transgenic G93R-sod1
zebrafish lines exhibit reductions in survival that become
evident around 18-22 months of age [40]. While prelim-
inary findings in our transgenic G93A-SOD1-GFP zebra-
fish did not reveal any noticeable differences in survival
(data not shown), it is possible based on the findings in
the other model that the 60 week time frame for the
current study was too short to detect quantifiable differ-
ences, and studies are currently ongoing to determine
when or if survival is affected in our model. TakenFigure 7 Neuromuscular phenotype of transgenic ALS zebrafish. Tran
around 20 weeks of age, subsequent alterations in innervation patterns at
which reflect a sequence of events that resembles the human disease coutogether, both models depict a sequence of events that
supports the “dying-back” theory in ALS, where defects
at the NMJ are the first insult and then lead to progres-
sive distal axonal degeneration and subsequent MN loss
[3,4,24,42].
This newly established ALS model provides an add-
itional system that will supplement our understanding of
ALS neuromuscular pathology in the context of disease
progression. While we observe significant neuromuscu-
lar defects that reflect a characteristic distal-to-proximal
ALS disease course, there are still unanswered questions
that should be addressed to understand why the disease
course is not as severe in zebrafish as it is in G93A-
SOD1 rodents, and why drastic locomotor deficits are
not observed even in the context of MN loss. A possible
explanation for the reduced disease severity could relate
to the relative expression levels of mutant SOD1 in the
transgenic models. Our data indicate that G93A-SOD1-
GFP expression levels were approximately 64% that of
the endogenous zebrafish wtSOD1 (Figure 2C), whereas
transgenic G93A-SOD1 rodent models exhibit robust
levels of overexpression [22]. It is also possible that the
disease course is affected by the regenerative ability of
zebrafish; while neuronal regeneration is not prevalent
in human or rodent spinal cords, evidence of MN regen-
eration has been reported in zebrafish [58]. The
observed alterations in NMJ innervation patterns (Fig-
ure 4) support the possibility of compensatory reinner-
vation, and although we observe a decrease in MN
numbers in transgenic G93A-SOD1-GFP zebrafish, re-
generative markers must be examined in spinal cords to
understand what role regeneration plays in disease
pathogenesis in this model. Non-cell autonomous
effects including astrocytes and glial activation also have
a significant impact on disease progression in rodent
ALS models [1,2]; therefore, the contributions of these
cell types to disease pathogenesis should also be investi-
gated. The impact of G93A-SOD1-GFP expression on
other neuronal populations is also of interest, although
no effects were seen on the commissural axon of the
Mauthner neuron in the hindbrain, on sensory neurons
of the lateral line, or on Rohon-Beard sensory neurons insgenic G93A-SOD1-GFP zebrafish exhibit denervation at the NMJ
30 weeks of age, and evidence of MN loss around 40 weeks of age
rse.
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nally, a detailed analysis of MN axons using electron mi-
croscopy and IHC with advanced imaging techniques to
comprehend the mechanisms of axonal degeneration
throughout the disease course will provide important
insight into the “dying-back” mechanisms of MN degen-
eration in ALS [3,4,24,42].
Conclusions
In summary, the novel transgenic G93A-SOD1-GFP zeb-
rafish exhibit defects at the NMJ around 20 weeks of
age, subsequent alterations in innervation patterns at
30 weeks of age, and evidence of MN loss around
40 weeks of age (Figure 7). These neuromuscular find-
ings support the utilization of zebrafish as a model or-
ganism to investigate early events in ALS disease
pathogenesis for therapeutic development. Furthermore,
the generation of transgenic ALS zebrafish models
expressing other familial ALS mutations such as TDP43
should be considered, as they have the potential to pro-




All zebrafish (Danio rerio) were maintained and handled
in compliance with national and local animal welfare
bodies and utilized per approved protocols (University of
Michigan's Institutional Animal Care and Use Commit-
tee protocol #09835). Embryos were collected after
timed mating of adult AB strain zebrafish for micro-
injection to establish the transient ALS models or gener-
ate the transgenic ALS lines used in these studies.
Transgenic HB9:mGFP zebrafish [28] which express
GFP in MNs were used to confirm the MN identification
approach utilized for MN quantification. The transgenic
ALS zebrafish described in this manuscript are available
by contacting jamedowl@med.umich.edu, or if there is
sufficient interest we will provide the lines through the
Zebrafish International Resource Center (ZIRC; http://
zebrafish.org/zirc/home).
Transient overexpression of G93A-SOD1 in zebrafish
RNA generated from pCS2+ vectors allows for efficient
transient expression of proteins in zebrafish embryos. To
generate transient ALS zebrafish models, full length
clones to human wtSOD1 and G93A-SOD1 [13] were
subcloned into pCS2+ followed by restriction digest to
linearize the constructs for generation of RNA using the
mMessage mMachine SP6 kit (Ambion). The pCS2-
based zebrafish igf-I construct was provided by Dr.
Cunming Duan for igf-I RNA generation [59]. mRNA
was microinjected into the yolk sac of 1-4 cell embryos
and embryos were incubated at 28oC in 0.5X E2 mediauntil processing for IHC or western blotting as previ-
ously described [60,61]. For IHC, microinjected zebrafish
embryos and UIC zebrafish embryos were deyolked at 30
hpf and fixed overnight in 4% PFA. Fixed embryos were
washed with 1x PBS and blocked for 2 h at room
temperature in 2% BSA, 0.5% Triton-X 100 and 0.05%
DMSO before incubation with the SV2 primary antibody
(1:200; Developmental Studies Hybridoma Bank) over-
night at 4oC. Embryos were then washed and incubated
with AlexaFluor-594-conjugated anti-mouse secondary
antibody (1:250, Invitrogen) for 2 h at room temperature,
washed, and mounted onto glass slides using ProLong-
Gold antifade reagent (Invitrogen, Eugene, OR). Slides
were blinded and imaged using a Nikon AZ100 micro-
scope and NIS Elements BS software. The length from
the tip of the motor axon to the point where it exits the
spinal cord was measured for 5 axons per embryo, corre-
sponding to axons 13-17 using NIS Elements BS soft-
ware. A minimum of 30 embryos per condition over 3
independent experiments were assessed for each data set.
Western blotting using standard protocols [21,45] was
utilized to confirm SOD1 expression and activation of
downstream IGF-I pathways. Briefly, microinjected zeb-
rafish embryos and UIC zebrafish embryos were dechor-
ionated at 30 hpf and protein lysates were prepared in
RIPA buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 0.1% SDS, 1 mM Na deocycholate, 1% Triton X-
100, 0.1 trypsin units/L aprotinin, 10 mg/ml leupeptin,
and 50 mg/ml PMSF; 15 μl per embryo). Equal amounts
of protein were loaded into each lane of a 12.5% or 15%
polyacrylamide gel for analysis of phospho-Akt/phos-
pho-MAPK or SOD1 expression, respectively, and trans-
ferred to nitrocellulose. Blots were incubated with
primary antibodies overnight at 4oC followed by incuba-
tion with appropriate horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA). The following antibodies were utilized:
phospho-Akt (1:1000; Cell Signaling, Danvers, MA),
phospho-p44/42 MAPK (Thr202/tyr204; 1:1000; Cell
Signaling), SOD-100 (1:5000; Stressgen, Victoria,
Canada), and GAPDH (1:5000; Chemicon, Temecula,
CA). Results following enhanced chemiluminescence
with LumiGlO plus Peroxide reagent (Cell Signaling)
were detected using the BioRad ChemiDoc XRS imaging
system with Quantity One analysis software. GAPDH
was used to confirm equal protein loading.
Generation of transgenic ALS zebrafish lines
Stable transgenic zebrafish expressing G93A-SOD1-GFP
were generated using Tol2-mediated transgenesis [47].
Constructs were generated with the Gateway-based
cloning system using Tol2-constructs kindly provided by
Dr. Chi-Bin Chien. Final constructs utilized the pDEST
destination vector including a CMV promoter element,
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SV40 late polyadenylation signal [47]. cDNA (10 ng/μl)
was microinjected into 1-4 cell zebrafish embryos as
described above along with Tol2 transposase RNA
(100 ng/μl) to facilitate Tol2-mediated random integra-
tion into the genome. P0 transgenic embryos were raised
to maturity and screened for germline incorporation.
Successful generation of transgenic lines was evident via
GFP expression in F1 generation embryos, or alterna-
tively, via PCR analysis of genomic DNA from F1 gener-
ation embryos. Briefly, genomic DNA was extracted
from 24 hpf embryos following standard protocols [62]
and PCR-screened for the presence of incorporated
human SOD1 cDNA using the following primers: for-
ward 5’-TTCGAGCAGAAGGAAAGTAATGGA-3’, reverse
5’-ACATTGCCCAAGTCTCCAACATGC-3’. Character-
ization of established transgenic lines was performed on
F2 generation zebrafish and compared to age-matched
control AB strain zebrafish. Stable transgene expression
throughout the zebrafish lifespan and across generations
was confirmed by assessing GFP fluorescence at each
time point. Furthermore, western blotting was utilized
to assay G93A-SOD1-GFP protein expression levels in
transgenic 24-48 hpf embryos according to the protocol
detailed above. Results are representative of at least 3
independent experiments from 3 clutches and densi-
tometry results were normalized to GAPDH to quantify
protein expression levels using Quantity One analysis
software.
Zebrafish activity monitoring
Swimming behavior was assessed using the rapid detec-
tion Noldus Larvae Activity Monitoring System (http://
www.noldus.com/site/dpc200711027). An infrared cam-
era tracks fish movements over a defined time interval
and movements are then converted into distance tracks
for analysis according to multiple activity parameters using
the system’s proprietary software package, EthoVision
XT 6.0. The system accommodates various sized multi-
well plates to allow for quick and easy quantification of
movement throughout the lifespan of the transgenic
zebrafish. For activity monitoring, AB (n = 7) and trans-
genic G93A-SOD1-GFP (n = 11) zebrafish were moni-
tored weekly between the ages of 10 and 30 weeks and
every other week between 30 and 70 weeks of age, for
10 minutes to record spontaneous swimming behavior.
Results were analyzed for average swimming velocity and
time resting during the 10 minute monitoring interval.
Neuromuscular characterization
MN axonal and NMJ defects and degeneration were
examined by IHC per standard protocols [45,52,55].
Briefly, adult AB and transgenic G93A-SOD1-GFP zebra-
fish were euthanized at 10, 20, 30, 40, and 60 weeks ofage. Fish were fixed overnight in 2% PFA, cryoprotected
in PBS containing 30% sucrose and muscle tissue was
dissected and embedded in OCT for sectioning and IHC.
Longitudinal sections (20 μm) were obtained on a Leica
cryostat and then processed for IHC using our previously
published method [60,63]. Briefly, sections were blocked
for 30 minutes with 5% normal goat serum / 0.1% triton-
X100 / 1x PBS and incubated with AlexaFluor 647-
conjugated αBTX (1:1000; Molecular Probes, Invitrogen,
Carlsbad) for 30 minutes to label postsynaptic AChRs.
Sections were then washed and incubated overnight with
SV2 (1:200; Hybridoma Bank, Iowa City, IA) and NF
(1:1000; Chemicon) primary antibodies to label MN
axons. After washing, Alexa Fluor 594-conjugated IgG
secondary antibody (Molecular Probes) was applied for
2 h, followed by rinsing and mounting in Prolong Gold
antifade reagent with DAPI (Invitrogen). Slides were
blinded for z-stack imaging with a Zeiss Apotome or a
Nikon A1 laser scanning confocal system with TiE
microscope. Imaging was done at the University of Mich-
igan Microscopy & Image Analysis Core (http://www.
med.umich.edu/mil/index.htm) or the Morphology and
Image Analysis Core of the Michigan Diabetes Research
and Training Center (http://www.med.umich.edu/mdrtc/
cores/MIACCore/index.html), respectively.
Differences in NMJ integrity were determined by
examining SV2/NF and αBTX co-localization to calculate
the percent of innervated junctions and by examining
NMJ innervation patterns. The percent of innervated
synapses was determined by calculating the number of
AChR clusters fully or partially innervated by nerve
terminals as previously described using MetaMorph
(version 7.4.4, Molecular Devices, Sunnyvale, CA)
[40,45,50,64,65]. At least 3 random images per slide
were acquired from 3 zebrafish per time point, for a
minimum of 9 images per line. Elements software was
used to visualize orthogonal XZ and YZ views of the
z-seried to confirm colocalization. Qualitative assess-
ment of innervation patterns in the muscle consisted of
assessing branching patterns of individual fibers for at
least 3 images per slide from 3 zebrafish per time point
per condition. Innervation patterns were scored as long,
moderately branched or complex. Long axons (score of 1)
are axons that do not exhibit a major branch point along
the length of visible axonal segment. Moderately branched
axons are nerve fibers that exhibit a single major branch
point (score of 2) or two branch points (score of 3). Com-
plex innervation patterns consist of segments with three
or more major branches (score of 4+).
Motor neuron quantification
MN loss was determined by counting the total number
of MNs in spinal cord sections [66]. Adult AB and trans-
genic ALS zebrafish at 30, 40, and 60 weeks of age were
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and prepared for sectioning as described above for
muscle tissue. MNs in 20 μm cross-sections were labeled
with Cresyl violet Nissl stain (Catalog # C-3886; Sigma,
St. Louis, MO) as previously described [67]. Briefly, sec-
tions were stained with Cresyl violet and cleared and
dehydrated prior to mounting with DPX. Images were
acquired using a Nikon Microphot-FXA microscope and
the number of spinal MNs per spinal cord ventral horn
was quantified for multiple sections throughout the
spinal cord from at least 3 fish per line at each time
point. The approach identifying MNs by cell body size
and localization to the ventral horn was validated using
transgenic HB9:mGFP zebrafish.
Statistical analysis
All results are representative of at least 3 independent
experiments and slides were blinded prior to imaging
and analysis. Multiple independent transgenic ALS zeb-
rafish lines were generated to minimize any positional
effects of the transgene insertion. Statistical significance
was determined using one-way ANOVA followed by
Tukey’s multiple comparison test or linear regression
analysis (GraphPad Prism).
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